BMS-599626 in Patients With Advanced Solid Malignancies
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The purpose of this trial is to identify the highest oral dose of BMS-599626, a drug that is
directed against EGFR and HER2 proteins, that can be given safely on a daily schedule of 21
days with a 7 day rest period in patients with cancer who no longer benefit from other
commonly used treatments. The study will also test for other proteins that may be affected by
BMS-599626; and the level of study drug in the blood will be studied.